Challenge Prostate cancer is the most frequently occurring type of cancer in the western world, with over 1 million cases registered in 2012. Standard diagnostics involves tissue sampling (biopsies) in 12 locations in the prostate. In almost a quarter of cases only insignificant tumors are found, but often unnecessarily treated. Due to this superfluous sampling, 18% of patients experience complications and 2%-3% are hospitalised within 30 days.
Opportunity An aging population is driving the incidence of prostate cancer (3.6% annual growth rate). The cancer diagnostics market is growing with a CAGR of 8.8%, largely driven by prostate cancer and advances in imaging. The ultrasound market is expected to reach $7.6 billion by 2022.
Solution Researchers at the Technical University of Eindhoven have developed a way of using ultrasound to reveal the location of clinically significant tumors in the prostate. With this method, target biopsies can be taken which will reduce the chance of complications. Furthermore, by reducing the number of uncomfortable biopsies, more patients will adhere to their active surveillance schedules.
✓ Accurate detection of clinically significant tumors in the prostate
✓ Enables targeted biopsies
✓ Lowers healthcare costs
Status CUDI has demonstrated equivalent performance to MRI for targeted biopsies in a 150 patient prospective comparative trial conducted at the AUMC, and drives a significant decrease in the detection of clinically insignificant prostate cancer versus systematic biopsies.